The Immune Tolerance Network (ITN), the $144 million dollar clinical research effort that is leading the charge to develop more effective islet transplantation protocols, has officially moved from the University of Chicago to UCSF. The Immune Tolerance Network is a multinational research consortium co-sponsored by the National Institutes of Health and the Juvenile Diabetes Research Foundation. The ITN mission is to investigate new, highly specific 'tolerance' therapies for a variety of immune-mediated diseases including allergy, asthma, multiple sclerosis and diabetes. Our energetic Diabetes Center Director Jeffrey Bluestone, Ph.D. does double-duty as the Director of the ITN.

"With the ITN now officially here at UCSF, it really puts our scientists at the Diabetes Center at the very heart of islet transplantation," says Bluestone.